Imipramine in the treatment of social phobia.
We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.
Simpson
H B
HB
New York State Psychiatric Institute, Anxiety Disorders Clinic, NY 10032, USA.
Schneier
F R
FR
Campeas
R B
RB
Marshall
R D
RD
Fallon
B A
BA
Davies
S
S
Klein
D F
DF
Liebowitz
M R
MR
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D016037:Single-Blind Method
D000929:Antidepressive Agents, Tricyclic; D007099:Imipramine